Amgen and AstraZeneca report results from Phase III trial of Tezspire for CRSwNP

Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III WAYPOINT trial of Tezspire (tezepelumab-ekko) for treating chronic rhinosinusitis with nasal polyps (CRSwNP).